CAMBRIDGE, Mass., Sept. 5,
2023 /PRNewswire/ -- Leap Therapeutics, Inc.
(Nasdaq:LPTX), a biotechnology company focused on developing
targeted and immuno-oncology therapeutics, today announced that
Douglas E. Onsi, President and Chief
Executive Officer, will participate in two upcoming investor
conferences:
Leap Presentation Details:
H.C. Wainwright 25th Annual Global Investment
Conference
Date: Monday, September
11th, 2023
Time: 7:00 a.m. Eastern Time
Baird Global Healthcare Conference
Date: Wednesday, September
13th, 2023
Time: 3:10 p.m. Eastern Time
A replay of the pre-recorded H.C. Wainwright presentation and a
live webcast of the Baird fireside chat may be accessed on the
Investors page of the company's website at
https://investors.leaptx.com/, where a replay of the events will
also be available for a limited time.
About Leap Therapeutics
Leap Therapeutics (Nasdaq: LPTX) is focused on developing
targeted and immuno-oncology therapeutics. Leap's most advanced
clinical candidate, DKN-01, is a humanized monoclonal antibody
targeting the Dickkopf-1 (DKK1)
protein. DKN-01 is being developed in patients with
esophagogastric, gynecologic, and colorectal cancers. FL-301, is a
humanized monoclonal antibody targeting Claudin18.2, being
developed in patients with gastric and pancreatic cancer. Leap also
has preclinical antibody programs targeting Claudin18.2/CD137 and
GDF15. For more information about Leap Therapeutics, visit
http://www.leaptx.com or view our public filings with the SEC that
are available via EDGAR at http://www.sec.gov or via
https://investors.leaptx.com/.
CONTACT:
Douglas E. Onsi
President & Chief Executive Officer
Leap Therapeutics, Inc.
617-714-0360
donsi@leaptx.com
Matthew DeYoung
Investor Relations
Argot Partners
212-600-1902
matthew@argotpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/leap-therapeutics-to-participate-at-upcoming-investor-conferences-301917374.html
SOURCE Leap Therapeutics, Inc.